Author(s)

ShengLi Gu

Affiliation(s)

Division of Medicine, Nantong University Xinglin College, Nantong 226019, Jiangsu, China.

Corresponding Author

ShengLi Gu

ABSTRACT

Parkinson’s disease (PD) is a prevalent neurodegenerative disorder, with increasing evidence highlighting a strong link between its pathogenesis and intestinal microbiome dysbiosis. This review systematically elucidates the mechanistic pathways of the microbiota–gut–brain axis in PD, emphasizing how gut dysbiosis promotes α-synuclein misfolding and propagation via the vagus nerve, thereby initiating neuroinflammation and dopaminergic neuronal loss. It further examines the critical role of the microbiota–immune–neural signaling network in driving disease progression. In addition, the therapeutic potential and current limitations of microbiota-targeted interventions, including fecal microbiota transplantation, prebiotics, probiotics, and dietary modulation, are evaluated. Collectively, current evidence highlights the gut–brain axis as a key framework in understanding PD etiology and underscores the intestine as a promising site for early intervention and the development of mechanism-based therapies.

KEYWORDS

Parkinson’s disease; Gut microbiota; α-synuclein; Neurodegenerative disease; Neuroinflammation; Microecological therapy

CITE THIS PAPER

ShengLi Gu. From gut to brain: targeting the microbiota axis for novel therapeutic avenues in parkinson’s disease. Journal of Pharmaceutical and Medical Research. 2026, 8(1): 47-50. DOI: https://doi.org/10.61784/jpmr3066.

REFERENCES

[1] Kumar B, Pandey M, Fayaz F, et al. Applications of Exosomes in Targeted Drug Delivery for the Treatment of Parkinson's Disease: A Review of Recent Advances and Clinical Challenges. Current Topics in Medicinal Chemistry, 2020, 20(30): 2777-2788.

[2] Jost ST, Kaldenbach MA, Antonini A, et al. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Movement Disorders, 2023, 38(7): 1236-1252.

[3] Zhang H, Wang YL. Pathogenesis and therapeutic advances of Parkinson's disease. Chinese Journal of Practical Nervous Diseases, 2021, 24(15): 1371-1380.

[4] Shen X, Sun ZH. Research progress on the microbiota-gut-brain axis and neurological diseases. Chinese Journal of Biotechnology, 2021, 37(11): 3781-3788.

[5] Kumar D, Bishnoi M, Kondepudi KK, et al. Gut Microbiota-Based Interventions for Parkinson's Disease: Neuroprotective Mechanisms and Current Perspective. Probiotics and Antimicrobial Proteins, 2025, 17(4): 2438-2460.

[6] Ran Z, Mu BR, Wang DM, et al. Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota. Molecular Neurobiology, 2025, 62(4): 5273-5296.

[7] Challis C, Hori A, Sampson TR, et al. Gut microbiota-independent α-synuclein pathology in germ-free mice. Nature Neuroscience, 2020, 23(10): 1229-1238.

[8] Chen SG, Stribinskis V, Rane MJ, et al. Exposure to bacterial amyloids promotes α-synuclein aggregation in mice. Scientific Reports, 2021, 11(1): 2383.

[9] Wang Y, Li L, Wu Y, et al. CD44 deficiency represses neuroinflammation and rescues dopaminergic neurons in a mouse model of Parkinson's disease. Pharmacological Research, 2022, 177: 106133.

[10] Kleine Bardenhorst S, Cereda E, Severgnini M, et al. Gut microbiota dysbiosis in Parkinson disease: A systematic review and pooled analysis. European Journal of Neurology, 2023, 30(11): 3581-3594.

[11] Lubomski M, Xu X, Holmes AJ, et al. The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies. Frontiers in Aging Neuroscience, 2022, 14: 875261.

[12] Ferreiro AL, Choi J, Ryou J, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Science Translational Medicine, 2023, 15(700): eabo2984.

[13] Zhang F, Deng Y, Wang H, et al. Gut microbiota-mediated ursodeoxycholic acids regulate the inflammation of microglia through TGR5 signaling after MCAO. Brain Behavior and Immunity, 2024, 115: 667-679.

[14] Chen P, Geng X. Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38(1): 2225800.

[15] De Sciscio M, Bryant RV, Haylock-Jacobs S, et al. Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability. NPJ Parkinson's Disease, 2025, 11(1): 203.

[16] Bruggeman A, Vandendriessche C, Hamerlinck H, et al. Safety and efficacy of FMT in mild-to-moderate PD (GUT-PARFECT): a double-blind, placebo-controlled phase 2 trial. EClinicalMedicine, 2024, 71: 102563.

[17] Tan AH, Lim SY, Chong KK, et al. Probiotic Lactobacillus and Bifidobacterium improve constipation and inflammatory markers in Parkinson's disease. Frontiers in Neurology, 2023, 14: 1195632.

[18] Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology, 2016, 87(12): 1274-1280.

[19] Shih LC, Lin RJ, Chen YL, et al. Unravelling the mechanisms of underweight in Parkinson's disease by investigating into the role of gut microbiome. NPJ Parkinson's Disease, 2024, 10(1): 28.

[20] Maraki MI, Yannakoulia M, Xiromerisiou G, et al. Mediterranean diet is associated with a lower probability of prodromal Parkinson's disease and risk for Parkinson's disease/dementia with Lewy bodies: A longitudinal study. European Journal of Neurology, 2023, 30(4): 934-942.

[21] Paoli A, Mancin L, Bianco A, et al. Ketogenic Diet and Microbiota: Friends or Enemies?. Genes, 2019, 10(7): 534.

[22] Boktor JC, Sharon G, Verhagen Metman LA, et al. Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome. Movement Disorders, 2023, 38(3): 399-409.

[23] Tetz G, Tetz V. Bacteriophages as potential contributors to Parkinson's disease pathogenesis. Scientific Reports, 2021, 11: 24617.

[24] Xu Y, Zhang L, Lin C, et al. Evaluating non-motor outcomes of gut microbiota-targeted therapy in Parkinson's disease. Translational Neurodegeneration, 2023, 12(1): 42.